Table 3. Determinants of occurrence of TB disease in study patients in Ethiopia during and after isoniazid preventive therapy use, September 2005 to October 2013 (n = 4,484).
| While taking IPT | After Completing IPT | |||||||
|---|---|---|---|---|---|---|---|---|
| Variable | Sub-category | Person Years | TB | Hazard Ratio (95% CI) |
Person Years | TB | Hazard Ratio (95% CI) |
P value* |
| Age | <15 | 240 | 2 | 620 | 4 | |||
| ≥15 | 1930 | 22 | 0.91 (0.17–4.81) | 9640 | 60 | 0.9 (0.3–2.66) | 0.799 | |
| Gender | Female | 1380 | 13 | 6630 | 37 | |||
| Male | 790 | 11 | 1.45 (0.65–3.25) | 3630 | 27 | 1.27 (0.77–2.09) | 0.794 | |
| Baseline WHO Stage | I or II | 870 | 8 | 4340 | 24 | |||
| III or IV | 1300 | 16 | 1.2 (0.51–2.84) | 5920 | 40 | 1.24 (0.74–2.07) | 0.909 | |
| Baseline CD4 Count | <100 | 390 | 5 | 2090 | 13 | |||
| 100–349 | 1310 | 13 | 0.58 (0.2–1.65) | 6910 | 43 | 0.79 (0.42–1.48) | 0.720 | |
| ≥350 | 460 | 6 | 0.71 (0.21–2.43) | 1250 | 8 | 0.77 (0.31–1.92) | 0.975 | |
| Treatment Status | IPT only | 400 | 9 | 840 | 20 | |||
| ART and IPT | 1770 | 15 | 0.51 (0.21–1.21) | 9420 | 44 | 0.2 (0.11–0.36) | 0.156 | |
*Test for interaction for factor with time